Tier 2 — strong

Effects of quercetin supplementation on endothelial dysfunction biomarkers and depression in post-myocardial infarction patients: A double-blind, placebo-controlled, randomized clinical trial

Fereshteh Dehghani, Mohammadreza Vafa, Ali Ebrahimkhani, Mihnea-Alexandru Găman, Seyed Hashem Sezavar Seyedi Jandaghi
Clinical nutrition ESPEN 2023 56:73-80

Bibliography

PubMed
PMID 37344086
DOI
10.1016/j.clnesp.2023.04.019
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflict of interest.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample88 post-infarction adults randomized; 76 completed
InterventionQuercetin 500 mg/day versus placebo
Duration8 weeks
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2023, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled trial. Sample/model: 88 post-infarction adults randomized; 76 completed. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: 8 weeks.

Quercetin did not significantly improve ICAM-1, VCAM-1 or depression compared with placebo.

Specific secondary-prevention population and short follow-up. Companion inflammatory-outcome reports use the same registered trial.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin did not significantly improve ICAM-1, VCAM-1 or depression compared with placebo.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; 8 weeks.

What this study can and cannot tell us

  • Specific secondary-prevention population and short follow-up. Companion inflammatory-outcome reports use the same registered trial.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effects of quercetin supplementation on inflammatory factors and quality of life in post-myocardial infarction patients: A double blind, placebo-controlled, randomized clinical trial
Fereshteh Dehghani et al. · Phytotherapy research : PTR · 2021
Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology